Skip to main content

Table 3 Unadjusted and adjusted hazard ratios for COPD exacerbations according to IgG subclass levels in the MACRO and STATCOPE cohorts

From: Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD

MACRO – Time to first Exacerbation

IgGa

Univariate analysis

Multivariate analysisb

Hazard Ratio (95% CI)

P

Hazard Ratio (95% CI)

P

IgG1

1.43 (1.23–1.67)

< 0.001

1.30 (1.10–1.54)

0.002

IgG2

1.29 (1.15–1.45)

< 0.001

1.19 (1.05–1.35)

0.006

IgG3

0.99 (0.88–1.11)

0.84

0.95 (0.85–1.07)

0.39

IgG4

1.09 (1.02–1.17)

0.009

1.05 (0.98–1.13)

0.17

STATCOPE – Time to first Exacerbation

IgGa

Hazard Ratio (95% CI)

P

Hazard Ratio (95% CI)

P

IgG1

1.45 (1.20–1.75)

< 0.001

1.25 (1.02–1.54)

0.035

IgG2

1.32 (1.15–1.52)

< 0.001

1.17 (1.01–1.36)

0.046

IgG3

1.10 (0.98–1.25)

0.11

0.99 (0.87–1.13)

0.90

IgG4

1.01 (0.94–1.08)

0.76

0.96 (0.89–1.04)

0.33

  1. aIgG subclass levels expressed using a negative-log transformation (base 2), with one-unit increase on this log scale being equivalent to a 50% decrease of IgG subclass levels. bAdjusted hazard ratios for IgG levels were calculated using a Cox Proportional Hazards model with adjustments for the following covariates: study drug (azithromycin vs. placebo in MACRO - First cohort; simvastatin vs. placebo in STATCOPE - Replication cohort), age, gender, ethnicity (Caucasian vs. Non-Caucasian), FEV1 (% of predicted values), smoking status (current vs. former smokers), oxygen dependence, inhaled corticosteroid use, and treatment with systemic steroids in previous year. Legend: 95% CI = 95% Confidence Interval